Role and mechanisms of SGLT-2 inhibitors in the treatment of …

Sep 21, 2023 · Diabetic kidney disease (DKD) is a chronic inflammatory condition that affects approximately 20-40% of individuals with diabetes. Sodium-glucose co-transporter 2 (SGLT-2) …

CouponFollow Extension

40%
OFF

Role And Mechanisms Of SGLT-2 Inhibitors In The Treatment Of …

1 week from now

Sep 21, 2023 · Diabetic kidney disease (DKD) is a chronic inflammatory condition that affects approximately 20-40% of individuals with diabetes. Sodium-glucose co-transporter 2 (SGLT-2) …

nih.gov

08%
OFF

The Outcomes Of SGLT-2 Inhibitor Utilization In Diabetic Kidney ...

1 week from now

1 day ago · SGLT-2i usage and outcomes in diabetic KTR. After a median follow-up of 3.4 years, the mortality rate among SGLT-2i users was significantly lower, with 2.08% (41 out of 1970, …

nature.com

FAQs about Role and mechanisms of SGLT-2 inhibitors in the treatment of … Coupon?

What is SGLT-2 inhibition?

The concept of inhibition of SGLT-2 marks a departure in how diabetes is viewed and approached for treatment. SGLT-2 inhibitors have a novel mechanism of action that is independent of insulin secretion and action. These agents block glucose reabsorption, leading to urinary glucose excretion. ...

What are the clinical effects of SGLT2 inhibitors?

In addition to glucose control, SGLT2 inhibitors have been shown to have beneficial effects on body weight, systolic blood pressure, and on the risks for major cardiovascular and renal events. In this section, we provide an overview of the clinical effects of SGLT2 inhibitors in patients with T2D and in obese individuals without diabetes. ...

Are SGLT2 inhibitors effective in the treatment of diabetes mellitus?

Scheen, A. J. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs75, 33–59 (2015). Scheen, A. J. & Paquot, N. Metabolic effects of SGLT2 inhibitors beyond increased glucosuria: a review of clinical evidence. Diabetes Metab.40, S4–S11 (2014). ...

Do SGLT2 inhibitors reduce plasma volume?

A reduction in plasma volume has been observed in animal and human studies of SGLT2 inhibitors, most notably in the first several months of use 11. SGLT2 inhibitors may also alter sodium handling in cardiac myocytes independently of their natriuretic effects. ...

Do SGLT2 inhibitors suppress proinflammatory and profibrotic pathways?

LV indicates left ventricular; and SGLT2, sodium-glucose cotransporter-2. As described above, SGLT2 inhibitors have been associated with suppression of proinflammatory and profibrotic pathways in several animal models. Most of these studies have either been in vitro, or have looked at effects in kidney tissue. ...

How many SGLT-2 inhibitors are there?

To date, there are four SGLT-2 inhibitors: canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin that are approved by Food Drug Administration (FDA) for their use in adults. ...